Stephen Hardt is the Vice President Supply Chain and External Manufacturing for Allogene Therapeutics, overseeing a broad network of contract manufacturers and suppliers and leading Allogene’s planning, logistics and distribution functions. Stephen has over 25 years of experience in technical operations, supply chain strategy, manufacturing and portfolio management. Prior to joining Allogene, he worked for Genentech for 15 years where he held various global leadership roles most recently as the Vice President of Technical Product Management and Network Strategy. In this role, Stephen developed and executed product strategies for a portfolio of over 40 products, led the biologic and small molecule CMC team system and his team oversaw numerous global product launches including Tecentriqâ, Ocrevusâ and Hemlibraâ. At Genentech, Stephen was also the Global Head of Contract Manufacturing Operations, providing leadership for an extensive external network of drug substance, drug product and clinical manufacturing sites. Prior to joining Genentech, Steve held various senior roles across the biotech and diagnostic industries. Steve holds a bachelor’s degree in biology from the University of California, San Diego.